Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
Delayed Quote. Delayed Nyse - 12/06 04:10:00 pm
51.48 USD   -5.14%
05:26pINSIDER SELL : Pfizer
MT
05:22pHealth Care Up As Moderna Slides -- Health Care Roundup
DJ
04:53pWall Street regains some ground with help from easing virus fears
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID vaccine: CDC expands booster rollout, OKs mixing shots

10/21/2021 | 02:10pm EST

WASHINGTON (AP) — Millions more Americans can get a COVID-19 booster and choose a different company’s vaccine for that next shot, federal health officials said Thursday.

Certain people who received Pfizer vaccinations months ago already are eligible for a booster and now the Centers for Disease Control and Prevention says specific Moderna and Johnson & Johnson recipients qualify, too. And in a bigger change, the agency is allowing the flexibility of “mixing and matching" that extra dose regardless of which type people received first.

The Food and Drug Administration had already authorized such an expansion of the nation's booster campaign on Wednesday, and it was also endorsed Thursday by a CDC advisory panel. CDC Director Dr. Rochelle Walensky had the final word on who gets the extra doses.

“We’re at a different place in the pandemic than we were earlier” when supply constraints meant people had to take whatever shot they were offered, noted CDC adviser Dr. Helen Keipp Talbot of Vanderbilt University.

She called it “priceless” to be able to choose a different kind for the booster if, for example, someone might be at risk for a rare side effect from a specific vaccine.

There still are restrictions on who qualifies and when for a booster. Starting six months past their last Pfizer vaccination, people are urged to get a booster if they're 65 or older, nursing home residents, or at least 50 and at increased risk of severe disease because of health problems. Boosters also were allowed, but not urged, for adults of any age at increased risk of infection because of health problems or their jobs or living conditions. That includes health care workers, teachers and people in jails or homeless shelters.

The same booster qualifications apply to Moderna recipients. Moderna's booster will come at half the dose of the original two shots.

As for recipients of the single-shot J&J vaccine, a COVID-19 booster is recommended for everyone at least two months after their vaccination. That's because the J&J vaccine hasn't proved as protective as the two-dose Moderna or Pfizer options.

The CDC panel didn't explicitly recommend anyone get a different brand than they started with but left open the option — saying only that a booster of some sort was recommended. And some of the advisers said they would prefer that J&J recipients receive a competitor's booster, citing preliminary data from an ongoing government study that suggested a bigger boost in virus-fighting antibodies from that combination.

About two-thirds of Americans eligible for COVID-19 shots are fully vaccinated, and the government says getting first shots to the unvaccinated remain the priority. While health authorities hope boosters will shore up waning immunity against milder coronavirus infections, all the vaccines still offer strong protection against hospitalizations and death.

And CDC's advisers wrestled with whether people who didn't really need boosters might be getting them, especially young, otherwise healthy adults whose only qualification was their job.

Dr. Sarah Long of Drexel University voiced concerns about opening those people to rare but serious side effects from another dose if they already were adequately protected.

“I have my own concerns that we appear to be recommending vaccines for people who I don’t think need it,” added Dr. Beth Bell of the University of Washington.

But she stressed that the vaccines work and that moving forward with the recommendations makes sense for the sake of being clear and allowing flexibility when it comes to boosters.

Despite the concerns by some members, the panels' votes ended up being unanimous.

The vast majority of the nearly 190 million Americans who are fully vaccinated against COVID-19 have received the Pfizer or Moderna options, while J&J recipients account for only about 15 million.

___

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 2.23% 162.94 Delayed Quote.3.53%
MODERNA, INC. -13.49% 265.33 Delayed Quote.193.60%
PFIZER, INC. -5.14% 51.48 Delayed Quote.44.09%
All news about PFIZER, INC.
05:26pINSIDER SELL : Pfizer
MT
05:22pHealth Care Up As Moderna Slides -- Health Care Roundup
DJ
04:53pWall Street regains some ground with help from easing virus fears
RE
04:36pWall Street regains some ground with help from easing virus fears
RE
04:00pWall Street closes up as easing in virus fears aids rebound
RE
02:32pCOVID-19 Reopening Plays Among Top Gainers While Vaccine Makers Tumble on Reports Omicr..
MT
10:35aBiohaven's migraine therapy shows rapid pain relief in late-stage study
RE
09:50aSouth Africa's Biovac to start making Pfizer-BioNTech COVID-19 vaccine in early 2022 - ..
RE
08:35aBiohaven's migraine therapy shows rapid pain relief in late-stage study
RE
05:27aNZ secures new Pfizer COVID-19 medicine
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 517 M - -
Net income 2021 21 236 M - -
Net Debt 2021 27 873 M - -
P/E ratio 2021 13,3x
Yield 2021 3,06%
Capitalization 289 B 289 B -
EV / Sales 2021 3,89x
EV / Sales 2022 3,56x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 51,48 $
Average target price 49,78 $
Spread / Average Target -3,31%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.44.09%304 610
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641
ABBVIE INC.8.18%210 113